# US 2025/0084175 A1 · GENERATION OF CHIMERIC ANTIGEN RECEPTOR mRNA MOLECULES FOR EXPRESSION IN PRIMARY NK CELLS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084175 A1
- Document ID: US20250084175A1
- Status: Published application
- Kind: A1
- Application number: 18/580,025
- Filed: 2022-07-14
- Published: 2025-03-13
- Earliest claimed: 2021-07-21
- Assignees: ImmunityBio, Inc.
- Applicants: Immunitybio, Inc.
- Inventors: Fereshteh PARVIZ
- Web page: https://patentgrep.com/patent/US20250084175A1

## CPC

- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4202: {Receptors, cell surface antigens or cell surface determinants}
- A61K 40/421: {Immunoglobulin superfamily}
- A61K 40/4211: {CD19 or B4}
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61K 40/4224: {Molecules with a "CD" designation not provided for elsewhere}
- A61K 40/46: Viral antigens
- A61P 35/00: Antineoplastic agents
- C07K 14/70521: {CD28, CD152}
- C07K 14/70532: {B7 molecules, e.g. CD80, CD86}
- C07K 14/70535: {Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- C12N 15/85: for animal cells
- C07K 2317/53: Hinge
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to novel chimeric antigen (CAR) mRNA molecules, the methods of generating the molecules and methods of treating cancer with the molecules.

## Claims

### Claim 1

A chimeric antigen receptor (CAR) comprising:
a T7 promoter, a spacer sequence, a signal peptide, an antigen binding domain, a hinge region, a transmembrane (TM) domain, and an intracellular domain;
wherein the signal peptide comprises a cluster of differentiation 64 (CD64) and/or an IgG heavy chain variable gene (IgGHv) signal peptide; and
wherein the antigen binding domain binds to an antigen selected from the group consisting of cluster of differentiation 19 (CD19), B-cell maturation antigen (BCMA), B7 homolog 4 (B7H4), SARS-CoV-2 spike, and cluster of differentiation 30 alpha (CD30α).

### Claim 2 (depends on 1)

The CAR of claim 1, wherein the signal peptide comprises SEQ ID NO: 1 or SEQ ID NO:2.

### Claim 3 (depends on 1)

The CAR of claim 1, wherein the antigen binding domain that binds to CD19 comprises at least 90%, at least 95%, or up to 100% sequence identity to SEQ ID NO:4.

### Claim 4 (depends on 1)

The CAR of claim 1, wherein the antigen binding domain that binds to BCMA comprises at least 90%, at least 95%, or up to 100% sequence identity to SEQ ID NO:5 or SEQ ID NO:6.

### Claim 5 (depends on 1)

The CAR of claim 1, wherein the antigen binding domain that binds to B7H4 comprises at least 90%, at least 95%, or up to 100% sequence identity to SEQ ID NO:7.

### Claim 6 (depends on 1)

The CAR of claim 1, wherein the antigen binding domain that binds to SARS-CoV-2 spike comprises at least 90%, at least 95%, or up to 100% sequence identity to SEQ ID NO:8.

### Claim 7 (depends on 1)

The CAR of claim 1, wherein the antigen binding domain that binds to CD30α comprises at least 90%, at least 95%, or up to 100% sequence identity to SEQ ID NO:57.

### Claim 8 (depends on 1)

The CAR of claim 1, wherein the hinge region is a cluster of differentiation 28 (CD28) hinge region having SEQ ID NO:9.

### Claim 9 (depends on 1)

The CAR of claim 1, wherein the TM domain is a CD28 TM domain having SEQ ID NO:10.

### Claim 10 (depends on 1)

The CAR of claim 1, wherein the intracellular domain comprises a co-stimulatory domain comprises a CD28 cytoplasmic domain having SEQ ID NO:11.

### Claim 11 (depends on 1)

The CAR of claim 1, wherein the intracellular signaling domain comprises a cluster of differentiation 3 zeta (CD3ζ) cytoplasmic domain having SEQ ID NO:12.

### Claim 12 (depends on 1)

The CAR of claim 1, wherein the CAR comprises an amino acid sequence having at least 90%, at least 95%, or up to 100% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO: 20, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:58.

### Claim 13 (depends on 1)

A nucleic acid construct encoding the CAR of claim 1, wherein the nucleic acid construct comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO: 27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 SEQ ID NO: 32 and SEQ ID NO:59.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

An expression vector encoding the CAR of claim 1.

### Claim 16 (depends on 15)

The expression vector of claim 15 having a nucleic acid sequence selected from the group consisting of SEQ ID NO:33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO:41, and SEQ ID NO:42.

### Claim 17

A modified primary Natural Kill (NK) cell modified with an RNA molecule comprising one or more nucleic acids of a T7 promoter, a spacer sequence, a signal peptide sequence portion, an antigen binding domain sequence portion, a hinge region sequence portion, a transmembrane (TM) domain sequence portion and an intracellular domain sequence portion;
wherein the signal peptide sequence comprises a sequence encoding cluster of differentiation 64 (CD64) and/or an IgG heavy chain variable gene (IgGHv);
wherein the antigen binding domain comprises a sequence encoding an antigen binding portion that binds to an antigen selected from the group consisting of cluster of differentiation 19 (CD19), B-cell maturation antigen (BCMA), B7 homolog 4 (B7H4), SARS-CoV-2 spike, and cluster of differentiation 30 alpha (CD30α); and
wherein the nucleic acid sequences are operably linked to each other as a single polynucleotide.

### Claim 18 (depends on 17)

The modified primary NK cell of claim 17, wherein the intracellular domain sequence portion comprises a CD28 cytoplasmic domain having SEQ ID NO: 11 and/or a cluster of differentiation 3 zeta (CD3ζ) cytoplasmic domain having SEQ ID NO: 12.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21 (depends on 13)

A method for generating modified primary CAR-NK cells comprising transfecting a primary NK cell with a recombinant nucleic acid construct of claim 13.

### Claim 22 (depends on 17)

A method of immunotherapy for treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a genetically modified NK cell of claim 17.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27 (depends on 17)

A pharmaceutical composition comprising a modified NK cell of claim 17 and a pharmaceutically acceptable carrier.
